Some good news: There was a concern that SGLT2 inhibitors would also increase the risk of urinary tract infection (one symptom of UTI is a persistent urge to urinate, per the Mayo Clinic), but research has failed to find that connection
In diet-induced obese mice, we validated the synergistic anti-obesity ability of such peptide conjugates above those of single agonists, without inducing the adverse effects of systemic estrogen action 16
But right now, its not a solution for opioid dependence
A hypothetical astrocyte-microglia lactate shuttle derived from a (1)H NMR metabolomics analysis of cerebrospinal fluid from a cohort of South African children with tuberculous meningitis
GLP1 medications such as semaglutide or tirzepatide have robust evidence and multiple FDA indications for obesity and diabetes, with average weightloss outcomes often greater than older agents
It's a windfall for some industries